Radiosynoviorthesis is a minimally invasive treatment for inflammatory joint disorders. It is an alternative to surgical synovectomy and is used when systemic treatment and intraarticular glucocorticosteroid injections have failed. This literature review summarizes the effectiveness of this method in various inflammatory joint disorders. A systematic literature search was performed in the PubMed, Embase, Web of Science and DOAJ databases. Depending on the type of inflammation and level of joint destruction, the effectiveness of therapy is 50-80%, up to even 90-100% in hemarthrosis. The present study demonstrates that the therapy is safe, with almost no side-effects. It provides long-term cost-effectiveness for patients due to its ambulatory characteristics, does not require rehabilitation, and leads to reduced use of other therapies. Moreover, it may be used as an independent type of therapy as well as a part of complex treatment. Given its benefits, the method should be considered by specialists of various fields.

This study outlines the diagnostic and therapeutic approaches - both pharmacological and non-pharmacological - used by Moroccan rheumatologists in managing fibromyalgia (FM). It also addresses other key aspects, such as assessing the psychosocial context of patients and referring them to other medical specialties.

The aim was to assess osteocalcin (OC) and N-terminal telopeptide of type I collagen (NTx) levels in men with ankylosing spondylitis (AS) and evaluate their relationship with the course of the disease and the structural and functional state of bone tissue.

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. NSAIDs are first-line therapy, but individual responses vary widely. We evaluated the efficacy and patient preference of three NSAIDs (celecoxib, meloxicam and naproxen) through Bayesian N-of-1 clinical trials to optimize axSpA management.

Anti-RNA polymerase III antibodies (ARA) are frequent in systemic sclerosis (SSc). However, the reported prevalence is variable among studies and some clinical associations are debated. We aimed (i) to update the recent data on overall ARA prevalence in SSc and heterogeneity between centres; and (ii) to describe their clinical associations.

To investigate anifrolumab's ability to treat cutaneous and extracutaneous manifestations of dermatomyositis (DM) refractory to conventional systemic therapies.

The objectives of this study were to investigate the role of total inflammation vascular volume (TIVV), a novel quantitative parameter obtained from 18-fluorodeoxyglucose (18F-FDG) PET/CT, in assessing disease activity and predicting relapses and aortic dilatation in patients with large-vessel (LV)-GCA.

To describe the outcomes of pregnancies exposed to IL-1 targeted therapies (anti-IL-1): anakinra and/or canakinumab.

SLE is an autoimmune disease characterized by the production of autoantibodies. Antibody affinities are defined by immunoglobulins, which include the immunoglobulin heavy-chain variable region (IGHV) genes, but the relationship between SLE and IGHV has not been fully elucidated. This study aimed to investigate the association between clinical features of SLE and IGHV.

Rheumatoid arthritis (RA) is a progressive autoimmune disease. During complex therapy, vitamin D supplementation could have an immunomodulatory effect and improve disease activity.

To quantify the influence of lifestyle factors on tumour necrosis factor inhibitor (TNFi) treatment response, in axial spondyloarthritis (axSpA).

Physician global assessments (PhyGAs) are commonly performed in randomized controlled trials (RCTs) in SSc. However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore perceptions of the PhyGA, its role in RCTs and how physicians perform their own assessment.

The aim of this study was to develop a systematic review of quantitative studies focused on identifying factors associated with delay in diagnosing and treating adult patients with SLE. Electronic searches were conducted in Scopus, PubMed, and Web of Science for studies published up to 15 July 2024. Inclusion criteria were studies in adult patients that estimated delay in diagnosis and/or treatment, and associated barriers and facilitators. The Joanna Briggs Institute (JBI) Checklist was used to assess the quality of the studies. A total of 25 studies were included. The estimated median delay in diagnosis was 18 months [interquartile range (IQR) 0-32.3], and the time to treatment from diagnosis was 2.09 months (IQR 0.0-5.05). The median delay in diagnosis was 14.09 months (IQR 0.0-18.5) in men and 29.55 months (IQR 1.1-144.0) in women (n = 5). Early-onset SLE had a median delay of 3.88 months (IQR 1.5-9.1), while late-onset SLE had a median delay of 10.10 months (IQR 3.0-38.0) (n = 3). The barriers identified were the number of physicians consulted, misdiagnoses, lack of prompt access to a specialist, and lack of knowledge of the disease. The average quality of the studies was 6.4. The factors associated with diagnostic delay were being female, White, or of multiple races, having a less severe disease presentation, and older age. The reported median delays in the diagnosis and treatment of SLE are 18 months and 2.09 months, respectively. There is no consensus on defining diagnosis and/or treatment in SLE patients or a unified estimation method.

The ASAS consensus defines 'early axial spondyloarthritis (axSpA)' as symptom duration ≤2 years, a definition derived from expert opinion due to limited evidence. We performed a meta-analysis of randomized placebo-controlled trials (RCTs) of biologic and targeted synthetic DMARDs (bDMARDs/tsDMARDs) in axSpA to assess the impact of symptom duration on treatment response.

To validate the performance of the 2022 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for Takayasu arteritis (TAK) in a China cohort and examine its performance in clinical practices.